Kitov Pharmaceuticals (NASDAQ:KTOV) was upgraded by stock analysts at HC Wainwright from a “neutral” rating to a “buy” rating in a report issued on Tuesday, November 21st, Marketbeat reports. The brokerage presently has a $10.00 target price on the stock. HC Wainwright’s price objective indicates a potential upside of 385.44% from the stock’s previous close.
Kitov Pharmaceuticals (KTOV) traded down $0.08 on Tuesday, hitting $2.06. The stock had a trading volume of 117,637 shares, compared to its average volume of 242,685. Kitov Pharmaceuticals has a fifty-two week low of $1.27 and a fifty-two week high of $3.78.
COPYRIGHT VIOLATION WARNING: “Kitov Pharmaceuticals (KTOV) Raised to “Buy” at HC Wainwright” was originally posted by StockNewsTimes and is the property of of StockNewsTimes. If you are viewing this report on another domain, it was stolen and republished in violation of US & international copyright and trademark laws. The correct version of this report can be accessed at https://stocknewstimes.com/2017/12/06/kitov-pharmaceuticals-holdings-ltd-ktov-lifted-to-buy-at-hc-wainwright.html.
About Kitov Pharmaceuticals
Kitov Pharmaceuticals Holdings Ltd is an Israel-based company that develops non-steroidal anti-inflammatory drugs that treat pain without raising blood pressure, thus avoiding the increased risk of heart attacks, strokes or death.
Receive News & Ratings for Kitov Pharmaceuticals Holdings Ltd Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kitov Pharmaceuticals Holdings Ltd and related companies with MarketBeat.com's FREE daily email newsletter.